Balance Sheet
Cash Flow Statement
AmortizationAmortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Genmab A (GNMSF) Amortization (2023 - 2025)

Historic Amortization for Genmab A (GNMSF) over the last 3 years, with Q4 2025 value amounting to $9.1 billion.

  • Genmab A's Amortization rose 42795.14% to $9.1 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $9.1 billion, marking a year-over-year increase of 42795.14%. This contributed to the annual value of $9.1 billion for FY2025, which is 42795.14% up from last year.
  • Per Genmab A's latest filing, its Amortization stood at $9.1 billion for Q4 2025, which was up 42795.14% from $1.7 billion recorded in Q3 2025.
  • Genmab A's 5-year Amortization high stood at $9.1 billion for Q4 2025, and its period low was $15.0 million during Q4 2023.
  • For the 3-year period, Genmab A's Amortization averaged around $2.9 billion, with its median value being $1.7 billion (2025).
  • In the last 5 years, Genmab A's Amortization soared by 1142000.0% in 2024 and then skyrocketed by 42795.14% in 2025.
  • Genmab A's Amortization (Quarter) stood at $15.0 million in 2023, then soared by 11420.0% to $1.7 billion in 2024, then skyrocketed by 427.95% to $9.1 billion in 2025.
  • Its Amortization was $9.1 billion in Q4 2025, compared to $1.7 billion in Q3 2025 and $1.8 billion in Q2 2025.